Glaxosmithkline traded at $52.14 this Wednesday March 18th, decreasing $6.98 or 11.81 percent since the previous trading session. Looking back, over the last four weeks, Glaxosmithkline lost 14.31 percent. Over the last 12 months, its price rose by 31.83 percent. Looking ahead, we forecast Glaxosmithkline to be priced at 52.28 by the end of this quarter and at 49.08 in one year, according to Trading Economics global macro models projections and analysts expectations.
GlaxoSmithKline PLC is a global healthcare company. The Company operates through two segments: Pharmaceuticals and Vaccines. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases. The Company makes a range of prescription medicines and vaccines products. The Pharmaceuticals business discovers, develops and commercializes medicines to treat a range of acute and chronic diseases. The Vaccines business provides vaccines for people of all ages from babies and adolescents to adults and older people. It has a portfolio of medicines in respiratory and HIV. Its Pharmaceuticals business includes Respiratory, HIV, Specialty products, and Classic and Established products. Its Vaccines business has a portfolio of over 40 pediatric, adolescent, adult, older people and travel vaccines.